MODULAÇÃO DA AUTOFAGIA COMO ESTRATÉGIA TERAPÊUTICA CONTRA O CÂNCER
Palavras-chave:
Autofagia. Câncer. Inibição/Ativação da Autofagia.Resumo
A autofagia é uma via metabólica essencial para a manutenção da homeostase celular, e pode desempenhar diferentes papéis dentro do contexto fisiológico e patológico. Por este motivo tem sido foco de muitos estudos por ser um alvo terapêutico promissor, principalmente contra o câncer, onde atua de maneira ambígua, podendo suprimir ou promover o tumor de acordo com o contexto. Compreender a base molecular desse mecanismo é de interesse emergente para se alcançar terapias eficazes utilizando a modulação da autofagia. Neste trabalho, realizou-se uma revisão da literatura para abordar o papel da autofagia na biologia do câncer e como ela pode ser usada como estratégia terapêutica antitumoral através de sua ativação ou inibição no tratamento de vários tipos e estágios do câncer.
Referências
Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo?San Pedro JM, Cecconi F, et al. Molecular definitions of autophagy and related processes. EMBO J. 2017;36(13):1811–36.
Saha S, Panigrahi DP, Patil S, Bhutia SK. Autophagy in health and disease: A comprehensive review. Biomed Pharmacother. 2018;104(February):485–95.
Yu L, Chen Y, Tooze SA. Autophagy pathway: Cellular and molecular mechanisms. Autophagy. 2018;14(2):207–15.
Nakamura S, Yoshimori T. New insights into autophagosome–lysosome fusion. J Cell Sci. 2017 Apr 1;130(7):1209–16.
Antonioli M, Di Rienzo M, Piacentini M, Fimia GM. Emerging Mechanisms in Initiating and Terminating Autophagy. Trends Biochem Sci. 2017 Jan;42(1):28–41.
Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, Kroemer G. Pharmacological modulation of autophagy: Therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2017;16(7):487–511.
Huang T, Song X, Yang Y, Wan X, Alvarez AA, Sastry N, et al. Autophagy and Hallmarks of Cancer. Crit Rev Oncog. 2018 Jun 21;23(5–6):247–67.
Chude CI, Amaravadi RK. Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors. Int J Mol Sci. 2017 Jun 16;18(6):1279.
Wilde L, Tanson K, Curry J, Martinez-Outschoorn U. Autophagy in cancer: A complex relationship. Biochem J. 2018;475(11):1939–54.
Martins WK, Baptista MS. Autophagy Modulation for Organelle-Targeting Autophagy Modulation for Organelle-Targeting Therapy. In: Autophagy in Current Trends in Cellular Physiology and Pathology. 2016. p. 350–90.
Marinkovi? M, Šprung M, Buljubaši? M, Novak I. Autophagy modulation in cancer: Current knowledge on action and therapy. Oxid Med Cell Longev. 2018;2018.
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541.
Yang Y, Yu L, Li J, Yuan YH, Wang XL, Yan SR, et al. Autophagy regulates the stemness of cervical cancer stem cells. Biol Targets Ther. 2017 Jun;Volume 11:71–9.
Peng Q, Qin J, Zhang Y, Cheng X, Wang X, Lu W, et al. Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2. J Exp Clin Cancer Res. 2017 Dec;36(1):171.
Zhao JX, Liu H, Lv J, Yang XJ. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro. Eur Rev Med Pharmacol Sci. 2014;18(17):2428–34.
Yang YP, Hu LF, Zheng HF, Mao CJ, Hu WD, Xiong KP, et al. Application and interpretation of current autophagy inhibitors and activators. Vol. 34, Acta Pharmacologica Sinica. Nature Publishing Group; 2013. p. 625–35.
Bhat P, Kriel J, Shubha Priya B, Basappa, Shivananju NS, Loos B. Modulating autophagy in cancer therapy: Advancements and challenges for cancer cell death sensitization. Biochem Pharmacol. 2018;147:170–82.
McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A. 2012;109(21):8253–8.
Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005 May 15;65(8):3336–46.
Martins WK, Costa ÉT, Cruz MC, Stolf BS, Miotto R, Cordeiro RM, et al. Parallel damage in mitochondrial and lysosomal compartments promotes efficient cell death with autophagy: The case of the pentacyclic triterpenoids. Sci Rep. 2015 Dec 27;5(1):12425.
Martins WK, Gomide AB, Costa ÉT, Junqueira HC, Stolf BS, Itri R, et al. Membrane damage by betulinic acid provides insights into cellular aging. Biochim Biophys Acta - Gen Subj. 2017 Jan;1861(1):3129–43.
Yamamoto a, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998;23(1):33–42.
Ahlberg J, Berkenstam A, Henell F, Glaumann H. Degradation of short and long lived proteins in isolated rat liver lysosomes. Effects of pH, temperature, and proteolytic inhibitors. J Biol Chem. 1985;260(9):5847–54.
Seglen PO, Grinde B, Solheim a E. Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin. Eur J Biochem. 1979 Apr 2;95(2):215–25.
Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266(26):17707–12.
Solomon VR, Lee H. Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol. 2009;625(1–3):220–33.
Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy. 2012;8(2):200–12.
Choi J-H, Yoon JS, Won Y-W, Park B-B, Lee YY. Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration. APMIS. 2012 Jul;120(7):597–604.
Zanotto-Filho A, Braganhol E, Klafke K, Figueiró F, Terra SR, Paludo FJ, et al. Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Lett. 2015 Mar;358(2):220–31.
Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K-J, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;0(0):15548627.2018.1474314.
Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: A double-edged sword of autophagy. Cancer Res. 2013;73(1):3–7.
Tsubone TM, Rocha CS, II-sei W, Stolf BS, Baptista MS MW. In vitro Autophagy Modulation with Chloroquine: Some Lessons to Learn. Adv Biochem Biotechnol. 2020;5(1098).
Mauvezin C, Nagy P, Juhász G, Neufeld TP. Autophagosome–lysosome fusion is independent of V-ATPase-mediated acidification. Nat Commun. 2015;6(May):7007.
Klionsky DJ, Elazar Z, Seglen PO, Rubinsztein DC. Does bafilomycin A1 block the fusion of autophagosomes with lysosomes? Autophagy. 2008;4(7):849–50.
Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Vol. 1833, Biochimica et Biophysica Acta - Molecular Cell Research. 2013. p. 3448–59.
Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 2005;12:1509–18.
Muñoz-Pinedo C, Martin SJ. Autosis: A new addition to the cell death tower of babel. Vol. 5, Cell Death and Disease. 2014. p. e1319–e1319.
Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ. 2008;15(1):171–82.
Ginet V, Puyal J, Rummel C, Aubry D, Breton C, Cloux AJ, et al. A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis. Autophagy. 2014;10(4):603–17.
Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021–31.
Cicchini M, Karantza V, Xia B. Molecular Pathways: Autophagy in Cancer—A Matter of Timing and Context. Clin Cancer Res. 2015 Feb;21(3):498–504.
Chang SB, Miron P, Miron A, Iglehart JD. Rapamycin Inhibits Proliferation of Estrogen-Receptor-Positive Breast Cancer Cells. J Surg Res. 2007;138(1):37–44.
Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, et al. Combined MTOR and autophagy inhibition. Autophagy. 2014 Aug 20;10(8):1391–402.
Crazzolara R, Cisterne A, Thien M, Hewson J, Baraz R, Bradstock KF, et al. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood. 2009;113(14):3297–306.
Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010;70(2):621–31.
Zhang D, Xia H, Zhang W, Fang B. The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor. Tumor Biol. 2016;37(1):1327–36.
Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity. Cancer Res. 2010 Jan 1;70(1):288–98.
Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E. Cancer Cell. 2010 Mar;17(3):249–61.
Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7(2):e38.
Miloševi? Z, Bankovi? J, Dini? J, Tsimplouli C, Sereti E, Dragoj M, et al. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma. Cell Oncol. 2018;41(4):409–26.
Caro-Vegas C, Bailey A, Bigi R, Damania B, Dittmer DP. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma. Shenk T, editor. MBio. 2019 Feb 19;10(1):1–13.
Zhang H, Berel D, Wang Y, Li P, Bhowmick NA, Figlin RA, et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One. 2013;8(1):e54918.
Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, et al. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. J Neurooncol. 2019;144(2):403–7.
Pitter KL, Galbán CJ, Galbán S, Saeed-Tehrani O, Li F, Charles N, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-Deficient PDGF-driven murine glioblastoma. PLoS One. 2011;6(1):1–11.
Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, et al. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatr Blood Cancer. 2017;64(7):1–9.
Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–67.
Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: Pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11(4):873–87.
Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, et al. Biomarkers of rsponse to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012;18(20):5816–28.
Lamoureux F, Thomas C, Crafter C, Kumano M, Zhang F, Davies BR, et al. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res. 2013;19(4):833–44.
Lamoureux F, Zoubeidi A. Dual inhibition of autophagy and the AKT pathway in prostate cancer. Autophagy. 2013;9(7):1119–20.
Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, et al. PI3K/p110? is a novel therapeutic target in multiple myeloma. Blood. 2010;116(9):1460–8.
Pereira JKN, Machado-Neto JA, Lopes MR, Morini BC, Traina F, Costa FF, et al. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. Eur J Cancer. 2015;51(14):2076–85.
Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K, et al. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(2):425–34.
Kong D, Yamori T, Yamazaki K, Dan S. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. Invest New Drugs. 2014;32(6):1134–43.
Enzenmüller S, Gonzalez P, Karpel-Massler G, Debatin KM, Fulda S. GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. Cancer Lett. 2013;329(1):27–36.
Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010;12(6):559–69.
Kuo W-L, Sharifi MN, Lingen MW, Ahmed O, Liu J, Nagilla M, et al. p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors. Califano JA, editor. PLoS One. 2014 Mar 5;9(3):e90171.
Zorea J, Prasad M, Cohen L, Li N, Schefzik R, Ghosh S, et al. IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer. Cell Death Dis. 2018;9(10).
Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6- dihydrobenzo[f]imidazo[1,2- d ][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2- methylpropanamide (GDC-0032): A ?-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robu. J Med Chem. 2013;56(11):4597–610.
Alqurashi N, Hashimi SM, Alowaidi F, Ivanovski S, Wei MQ. Dual mTOR/PI3K inhibitor NVP-BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E-BP1. Oncol Rep. 2018;40(2):1083–92.
Saha A, Blando J, Tremmel L, DiGiovanni J. Effect of metformin, rapamycin, and their combination on growth and progression of prostate tumors in HiMyc mice. Cancer Prev Res. 2015;8(7):597–606.
Sesen J, Dahan P, Scotland SJ, Saland E, Dang V-T, Lemarié A, et al. Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response. Alonso MM, editor. PLoS One. 2015 Apr;10(4):e0123721.
Liu Y-L, Yang P-M, Shun C-T, Wu M-S, Weng J-R, Chen C-C. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy. 2010 Nov;6(8):1057–65.
Yamamoto S, Tanaka K, Sakimura R, Okada T, Nakamura T, Li Y, et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res. 2008;28(3 A):1585–91.
Min A, Im S-A, Kim DK, Song S-H, Kim H-J, Lee K-H, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res. 2015;17(1):33.
Park JH, Ahn MY, Kim TH, Yoon S, Kang KW, Lee J, et al. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. Invest New Drugs. 2012 Oct;30(5):1887–98.
Zhang J, Wang J, Zhou Z, Park J-E, Wang L, Wu S, et al. Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors. Autophagy. 2018 Jul 30;14(6):1–17.
Kim DE, Kim Y, Cho DH, Jeong SY, Kim SB, Suh N, et al. Raloxifene induces autophagy-dependent cell death in breast cancer cells via the activation of amp-activated protein kinase. Mol Cells. 2015;38(2):138–44.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2020 Arquivos Catarinenses de Medicina
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
